Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the specification.

Listing of Claims:

1. (Original) Crystalline tiotropium bromide monohydrate.

2. (Currently Amended) Monoclinic crystalline tiotropium bromide monohydrate having a space group of P $2_1/n$.

3. (Previously Presented) Monoclinic crystalline tiotropium bromide monohydrate according to claim 2, having a primitive lattice type.

4. (Previously Presented) Monoclinic crystalline tiotropium bromide monohydrate according to claim 2, having 4 formula units per elementary cell.

5-8. (Cancelled)

9. (Withdrawn) A process for preparing monoclinic crystalline tiotropium bromide monohydrate, the process comprising:

(a) dissolving tiotropium bromide in water to obtain a solution;

(b) heating the resulting solution;

(c) adding activated charcoal to the heated solution;

(d) removing the activated charcoal; and

(e) allowing the solution to slowly cool to obtain monoclinic crystalline tiotropium bromide monohydrate.

10. (Withdrawn) A process for preparing monoclinic crystalline tiotropium bromide monohydrate, the process comprising:

(a) dissolving tiotropium bromide in water to obtain a solution;

(b) heating the resulting solution to more than 50°C;

(c) adding activated charcoal to the heated solution;

(d) removing the activated charcoal; and

(e) allowing the solution to slowly cool to obtain monoclinic crystalline tiotropium bromide monohydrate.

11. (Withdrawn) The process according to claim 10, wherein 0.4 to 1.5 kg of water are used per mole of tiotropium bromide in step (a).

12. (Withdrawn) The process according to claim 11, wherein 10 g to 50 g of activated charcoal per mole of tiotropium bromide is added in step (c).

13. (Withdrawn) The process according to claim 12, wherein the activated charcoal added in step (c) is stirred for between 5 and 60 minutes before it is removed in step (d).

14. (Withdrawn) The process according to claim 13, wherein step (d) is performed by filtration of the solution.

15. (Withdrawn) The process according to claim 14, wherein the solution of step (e) is cooled to a temperature of 20°C-25°C at a cooling rate of 1 to 10°C per 10 to 30 minutes.

16. (Withdrawn) A pharmaceutical composition comprising an effective therapeutic amount of crystalline tiotropium bromide monohydrate and a pharmaceutically acceptable excipient.

17. (Withdrawn) A method for treatment of diseases selected from the group consisting of allergic, anti-inflammatory, respiratory, genitourinary, CNS, ophthalmic, gastrointestinal, and nausea and vomiting which method comprises administering to a patient an effective therapeutic amount of a compound according to claim 1.

18. (Withdrawn) The method according to claim 17, wherein the disease is asthma or COPD.

19. (Withdrawn) A process for preparing monoclinic crystalline hydrates of tiotropium bromide, the process comprising:

(a) dissolving tiotropium bromide in water to obtain a solution;

(b) heating the resulting solution; and

(c) allowing the solution to slowly cool to obtain monoclinic crystalline hydrates of tiotropium bromide.

20. (Withdrawn) A process for preparing monoclinic crystalline hydrates of tiotropium bromide, the process comprising:

(a) dissolving tiotropium bromide in water to obtain a solution;

(b) heating the solution of step (a);

(c) adding activated charcoal to the heated solution of step (b);

(d) removing the activated charcoal from the solution of step (c); and

(e) allowing the solution to slowly cool to obtain monoclinic crystalline hydrates of tiotropium bromide.

21. (Withdrawn) The process of claim 20, wherein the solution of step (a) is heated to more than 50°C.